REFERENCES
2. Phelan K, Rogers RC, Boccuto L. Phelan-McDermid syndrome. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle; 2005. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1198/[Last accessed on 10 Jul 2023]
3. Phelan K, McDermid HE. The 22q13.3 deletion syndrome (Phelan-McDermid Syndrome). Mol Syndromol 2012;2:186-201.
4. Kolevzon A, Angarita B, Bush L, et al. Phelan-McDermid syndrome: a review of the literature and practice parameters for medical assessment and monitoring. J Neurodev Disord 2014;6:39.
5. National Organization for Rare Disorders. Phelan-cDermid sndrome. Available from: https://rarediseases.org/rare-diseases/phelan-mcdermid-syndrome/#affected-populations [Last accessed on 7 Jul 2023].
6. Betancur C, Buxbaum JD. SHANK3 haploinsufficiency: a "common" but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. Mol Autism 2013;4:17.
7. Soorya L, Kolevzon A, Zweifach J, et al. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. Mol Autism 2013;4:18.
8. Sarasua SM, Boccuto L, Sharp JL, et al. Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome. Hum Genet 2014;133:847-59.
9. Kohlenberg TM, Trelles MP, McLarney B, Betancur C, Thurm A, Kolevzon A. Psychiatric illness and regression in individuals with Phelan-McDermid syndrome. J Neurodev Disord 2020;12:7.
10. Kolevzon A, Delaby E, Berry-Kravis E, Buxbaum JD, Betancur C. Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature. Mol Autism 2019;10:50.
11. De Rubeis S, Siper PM, Durkin A, et al. Delineation of the genetic and clinical spectrum of Phelan-McDermid syndrome caused by SHANK3 point mutations. Mol Autism 2018;9:31.
12. Disciglio V, Lo Rizzo C, Mencarelli MA, et al. Interstitial 22q13 deletions not involving SHANK3 gene: a new contiguous gene syndrome. Am J Med Genet A 2014;164A:1666-76.
13. Ricciardello A, Tomaiuolo P, Persico AM. Genotype-phenotype correlation in Phelan-McDermid syndrome: A comprehensive review of chromosome 22q13 deleted genes. Am J Med Genet A 2021;185:2211-33.
14. Vondráčková A, Veselá K, Kratochvílová H, et al. Large copy number variations in combination with point mutations in the TYMP and SCO2 genes found in two patients with mitochondrial disorders. Eur J Hum Genet 2014;22:431-4.
16. Costales JL, Kolevzon A. Phelan-McDermid sndrome and SHANK3: iplications for teatment. Neurotherapeutics 2015;12:620-30.
17. Verhoeven WMA, Egger JIM, de Leeuw N. A longitudinal perspective on the pharmacotherapy of 24 adult patients with Phelan-McDermid syndrome. Eur J Med Genet 2020;63:103751.
19. Mantle D, Dybring A. Bioavailability of cenzyme Q(10): an overview of the absorption process and subsequent metabolism. Antioxidants 2020;9:386.
20. Weber C, Bysted A, Hłlmer G. The coenzyme Q10 content of the average Danish diet. Int J Vitam Nutr Res 1997;67:123-9.
21. Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol 2014;49:105e111.
22. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA 1998;95:8892-7.
23. Rötig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000;356:391-5.
24. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 2004;36:381-6.
25. Papucci L, Schiavone N, Witort E, et al. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem 2003;278:28220-8.
26. Kalayci M, Unal MM, Gul S, et al. Effect of coenzyme Q10 on ischemia and neuronal damage in an experimental traumatic brain-injury model in rats. BMC Neuroscience 2011;12:75.
27. Kumari S, Mehta SL, Milledge GZ, Huang X, Li H, Li PA. Ubisol-Q10 prevents glutamate-induced cell death by blocking mitochondrial fragmentation and permeability transition pore opening. Int J Biol Sci 2016; 12:688-700.
28. Degenhardt F, Niklowitz P, Szymczak S, et al. Genome-wide association study of serum coenzyme Q10 levels identifies susceptibility loci linked to neuronal diseases. Hum Mol Genet 2016;25:2881-91.
29. Somayajulu M, McCarthy S, Hung M, Sikorska M, Borowy-Borowski H, Pandey S. Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10. Neurobiol Dis 2005;18:618-27.
30. Moon Y, Lee KH, Park JH, Geum D, Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J Neurochem 2005;93:1199-208.
31. Hochberg J, Fortes da Silva FB. Latissimus dorsi myocutaneous flap to restore elbow flexion and axillary burn contracture: a report on two pediatric patients. J Pediatr Orthop 1982;2:565-8.
32. Müller T, Büttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003;341:201-4.
33. Shults CW, Beal MF, Fontaine D, Nakano K, Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998;50:793-5.
34. Cooper O, Seo H, Andrabi S, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012;4:141ra90.
35. Cucinotta F, Ricciardello A, Turriziani L, et al. Efficacy and safety of Q10 ubiquinol with vitamins b and e in neurodevelopmental disorders: a retrospective chart review. Front Psychiatry 2022;13:829516.
36. Psychiatric Association. Diagnostic and statistical manual of mental disorders. Med Health Care Phil 2014;17:241-244.
37. Soorya L, Leon J, Trelles MP, Thurm A. Framework for assessing individuals with rare genetic disorders associated with profound intellectual and multiple disabilities (PIMD): the example of Phelan McDermid Syndrome. Clin Neuropsychol 2018;32:1226-55.
38. Braconnier ML, Siper PM. Neuropsychological assessment in autism spectrum disorder. Curr Psychiatry Rep 2021;23:63.
39. Jacquemont S, Berry-Kravis E, Hagerman R, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology 2014;231:1237-50.
40. Sparrow SS, Cicchetti DV, Balla DA. Vineland adaptive behavior scales: second edition (Vineland II), survey interview form/caregiver rating form. Livonia, MN: Pearson Assessments; 2005. Available from: https://www.walmart.com/ip/Vineland-II-Vineland-Adaptive-Behavior-Scales-Survey-Forms-Manual-Interview-Form-Parent-Caregiver-Rating-Form-Pre-Owned-Unknown-Binding-B001P673SK-Do/702415787 [Last accessed on 7 Jul 2023].
41. Vaughan CA. Test Review: E. Schopler, M. E. Van Bourgondien, G. J. Wellman, & S. R. Love Childhood Autism Rating Scale (2nd ed.). Los Angeles, CA: Western Psychological Services, 2010. J Psychoeduc Assess 2011;29:489-93.
42. Guy W. Clinical global impressions ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute for Mental Health; 1976. Available from: https://ia600306.us.archive.org/35/items/ecdeuassessmentm1933guyw/ecdeuassessmentm1933guyw.pdf [Last accessed on 7 Jul 2023].
43. Guyatt GH, Townsend M, Berman LB, Keller JL. A comparison of likert and visual analogue scales for measuring change in function. J Chronic Dis 1987;40:1129-33.
44. Jaeschke R, Singer J, Guyatt GH. A comparison of seven-point and visual analogue scales. Data from a randomized trial. Control Clin Trials 1990;11:43-51.
45. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983;40:1228-31.
46. Constantino JN, Davis SA, Todd RD, et al. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 2003;33:427-33.
47. Lam KS, Aman MG. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord 2007;37:855-66.
48. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485-91. PMID: 3993694.
49. Tomchek SD, Dunn W. Sensory processing in children with and without autism: a comparative study using the short sensory profile. Am J Occup Ther 2007;61:190-200.
50. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998;26:257-68.
51. Achenbach TM, Rescorla LA. Manual for the ASEBA preschool forms and profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, and Families; 2000. Available from: https://www.researchgate.net/publication/243771256_Manual_for_the_ASEBA_Preschool_forms_profiles [Last accessed on 7 Jul 2023].
52. Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms and profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, and Families; 2001. Available from: https://store.aseba.org/MANUAL-FOR-THE-ASEBA-SCHOOL-AGE-FORMS-PROFILES/productinfo/505/ [Last accessed on 7 Jul2023].
53. McConachie H, Mason D, Parr JR, Garland D, Wilson C, Rodgers J. Enhancing the validity of a quality of life measure for autistic people. J Autism Dev Disord 2018;48:1596-611.
54. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998;28:551-8.
55. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Wien, Austria; 2020.
56. Ponson L, Gomot M, Blanc R, et al. 22q13 deletion syndrome: communication disorder or autism? Transl Psychiatry 2018;8:146.
57. Kann O, Kovács R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007;292:C641-57.
59. Carmeli E, Imam B, Bachar A, Merrick J. Inflammation and oxidative stress as biomarkers of premature aging in persons with intellectual disability. Res Dev Disabil 2012;33:369-75.
60. Valenti D, de Bari L, De Filippis B, Henrion-Caude A, Vacca RA. Mitochondrial dysfunction as a central actor in intellectual disability-related diseases: an overview of Down syndrome, autism, Fragile X and Rett syndrome. Neurosci Biobehav Rev 2014;46 Pt 2:202-17.
61. Alvarez-Mora MI, Rodriguez-Revenga L, Madrigal I, Guitart-Mampel M, Garrabou G, Milà M. Impaired mitochondrial function and dynamics in the pathogenesis of FXTAS. Mol Neurobiol 2017;54:6896-902.
62. Liu J, Wang L, Zhan S, Xia Y, Wang L. Coenzyme Q10 for Parkinson's disease. cochrane database of systematic reviews. Chichester: John Wiley & Sons, Ltd 1996; doi: 10.1002/14651858.CD008150.pub2.
63. Persico AM, Cucinotta F, Ricciardello A, Turriziani L. Autisms. Neurodevelopmental disorders. Elsevier; 2020. pp. 35-77.
64. Rossignol DA, Frye RE. Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism. Front Physiol 2014; 5:150.
65. Palmieri L, Persico AM. Mitochondrial dysfunction in autism spectrum disorders: cause or effect? Biochim Biophys Acta 2010; 1797:1130-7.
66. Palmieri L, Papaleo V, Porcelli V, et al. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry 2010; 15:38-52.
67. Chauhan A, Audhya T, Chauhan V. Brain region-specific glutathione redox imbalance in autism. Neurochem Res 2012; 37:1681-9.
68. Rose S, Melnyk S, Pavliv O, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry 2012; 2:e134.
69. Frustaci A, Neri M, Cesario A, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med 2012; 52:2128-41.
70. Tang G, Gutierrez Rios P, Kuo SH, et al. Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol Dis 2013; 54:349-61.
71. Gu F, Chauhan V, Chauhan A. Impaired synthesis and antioxidant defense of glutathione in the cerebellum of autistic subjects: alterations in the activities and protein expression of glutathione-related enzymes. Free Radic Biol Med 2013; 65:488-96.
72. El-Ansary A, Bjørklund G, Chirumbolo S, Alnakhli OM. Predictive value of selected biomarkers related to metabolism and oxidative stress in children with autism spectrum disorder. Metab Brain Dis 2017; 32:1209-21.
73. Yenkoyan K, Harutyunyan H, Harutyunyan A. A certain role of SOD/CAT imbalance in pathogenesis of autism spectrum disorders. Free Radic Biol Med 2018; 123:85-95.
74. Adams JB, Baral M, Geis E, et al. The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels. J Toxicol 2009; 2009:532640.
75. Ghezzo A, Visconti P, Abruzzo PM, et al. Oxidative stress and erythrocyte membrane alterations in children with autism: correlation with clinical features. PLoS One 2013;8:e66418.
76. Gorrindo P, Lane CJ, Lee EB, McLaughlin B, Levitt P. Enrichment of elevated plasma F2t-isoprostane levels in individuals with autism who are stratified by presence of gastrointestinal dysfunction. PLoS One 2013;8:e68444.
77. Rose S, Bennuri SC, Murray KF, Buie T, Winter H, Frye RE. Mitochondrial dysfunction in the gastrointestinal mucosa of children with autism: a blinded case-control study. PLoS One 2017;12:e0186377.
78. McElhanon BO, McCracken C, Karpen S, Sharp WG. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. Pediatrics 2014;133:872-83.
79. Frye RE, Cox D, Slattery J, et al. Mitochondrial dysfunction may explain symptom variation in phelan-mcdermid syndrome. Sci Rep 2016;6:19544.
81. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 2004;10:1033-9.
82. Adams JB, Audhya T, McDonough-Means S, et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr 2011;11:111.
83. Adams JB, Audhya T, Geis E, et al. Comprehensive nutritional and dietary intervention for autism spectrum disorder-a randomized, controlled 12-month trial. Nutrients 2018;10:369.
84. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsych Biol Psychiatry 1993;17:765-74.
85. Adams JB, George F, Audhya T. Abnormally high plasma levels of vitamin B6 in children with autism not taking supplements compared to controls not taking supplements. J Altern Complement Med 2006;12:59-63.
86. Mousavinejad E, Ghaffari MA, Riahi F, Hajmohammadi M, Tiznobeyk Z, Mousavinejad M. Coenzyme Q(10) supplementation reduces oxidative stress and decreases antioxidant enzyme activity in children with autism spectrum disorders. Psychiatry Res 2018;265:62-9.
87. Eldridge SM, Chan CL, Campbell MJ, et al. PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud 2016;2:64.
88. Matuleviciene A, Siauryte K, Kuiper E, Grabrucker AM. European Phelan-McDermid syndrome guideline consortium. Consensus recommendations on chewing, swallowing and gastrointestinal problems in Phelan-McDermid syndrome. Eur J Med Genet 2023;66:104763.
89. Serrada-Tejeda S, Martínez-Piédrola RM, Máximo-Bocanegra N, Sánchez-Herrera-Baeza P, Pérez-de-Heredia-Torres M. Descriptive analysis of adaptive behavior in Phelan-McDermid syndrome and autism spectrum disorder. Front Neurosci 2022;16:893003.
90. Droogmans G, Vergaelen E, Van Buggenhout G, Swillen A. Stressed parents, happy parents. An assessment of parenting stress and family quality of life in families with a child with Phelan-McDermid syndrome. J Appl Res Intellect Disabil 2021;34:1076-88.
